The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Out of pocket costs and financial toxicity experienced by patients in early phase clinical trials.
 
Ryan Huey
No Relationships to Disclose
 
Goldy George
No Relationships to Disclose
 
Penny Phillips
No Relationships to Disclose
 
Revenda White
No Relationships to Disclose
 
Siqing Fu
Research Funding - Anaeropharma (Inst); Aprea Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); Endocyte (Inst); Huya Bioscience International (Inst); Lilly (Inst); MacroGenics (Inst); Medivir (Inst); NeuPharma, Inc. (Inst); Novartis (Inst); OncoMed (Inst); Parexel International, LLC (Inst); Takeda (Inst)
 
Filip Janku
Stock and Other Ownership Interests - Trovagene
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; IFM Therapeutics; Immunome; Novartis; PureTech; Sequenom; Sotio; Synlogic; Trovagene; Valeant/Dendreon
Research Funding - Agios (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Fujifilm (Inst); Novartis (Inst); Piqur (Inst); Plexxikon (Inst); Roche (Inst); Symphogen (Inst)
Other Relationship - Bio-Rad
 
Daniel D. Karp
Consulting or Advisory Role - Black Beret Life Sciences
Research Funding - Phosplatin Therapeutics
Travel, Accommodations, Expenses - Phosplatin Therapeutics
 
Aung Naing
Consulting or Advisory Role - CytomX Therapeutics; Novartis
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Bristol-Myers Squibb; Calithera Biosciences; CytomX Therapeutics; EMD Serono; Healios; Immune Cell Therapy (I); Incyte; Karyopharm Therapeutics; Kyocera; Lilly; MedImmune; Merck; NCI; Neon Therapeutics; Novartis; Pfizer; Regeneron; TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences
 
Sarina Anne Piha-Paul
Research Funding - Abbvie (Inst); Aminex (Inst); Bayer (Inst); BlueLink (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); Samumed (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); TransThera Biosciences (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)
 
Vivek Subbiah
Consulting or Advisory Role - MedImmune
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; PharmaMar
 
Apostolia Maria Tsimberidou
Honoraria - Covance; Genentech
Consulting or Advisory Role - Roche
Research Funding - Baxter (Inst); Bayer (Inst); Boston Biomedical (Inst); EMD Serono (Inst); Foundation Medicine (Inst); IMMATICS (Inst); Karus Therapeutics (Inst); OBI Pharma (Inst); ONYX (Inst); Placon (Inst); Stem Cells, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Parker Institute for Cancer Immunotherapy (Inst)
 
Shubham Pant
Honoraria - 4D Pharma
Consulting or Advisory Role - Celgene; Halozyme; TYME
Research Funding - ArQule (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onco Response (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst)
 
Timothy A Yap
Honoraria - AstraZeneca; Pfizer
Consulting or Advisory Role - Aduro Biotech; Almac Diagnostics; AstraZeneca; Atrin Pharmaceuticals; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Cybrexa Therapeutics; EMD Serono; Ignyta; Janssen; Merck; Pfizer; Roche; Seagen; Tesaro; Vertex
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca; Bayer; Constellation Pharmaceuticals; Jounce Therapeutics; Kyowa Hakko Kirin; Lilly; Pfizer; Seagen; Tesaro; Vertex
Patents, Royalties, Other Intellectual Property - MD Anderson Cancer Center holds the intellectual property rights to IACS-010759 and its designated use. (Inst)
Travel, Accommodations, Expenses - EMD Serono; Pfizer; Tesaro
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Kelun; Lilly/ImClone; Merck Sharp & Dohme; Novartis; Orion; Peptomyc; Pfizer; SERVIER; Spectrum Pharmaceuticals
Research Funding - Bayer; Novartis
 
Funda Meric-Bernstam
Honoraria - Dialectica; Sumitomo Group
Consulting or Advisory Role - Aduro Biotech; Clearlight Diagnostics; DarwinHealth; Debiopharm Group; Genentech; Inflection Biosciences; Mersana; Origimed; Pieris Pharmaceuticals; Samsung Bioepis; Spectrum Pharmaceuticals; Xencor
Research Funding - Abbvie; Aileron Therapeutics; AstraZeneca; Bayer; Boehringer Ingelheim (I); Calithera Biosciences; Curis; CytomX Therapeutics; Daiichi Sankyo; Debiopharm Group; eFFECTOR Therapeutics; Genentech; GlaxoSmithKline; Guardant Health (Inst); Jounce Therapeutics; Novartis; Pfizer; PUMA Biotechnology; Taiho Pharmaceutical; Zymeworks
 
Ya-Chen T. Shih
Research Funding - Novartis (Inst)
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena; Presagia
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Adaptimmune; Alphasights; Axiom Biotechnologies; Baxter; Bayer; Eisai; Genentech; Gerson Lehrman Group; GroupH; Guidepoint Global; Janssen; Medscape; Merrimack; Numab; Pfizer; Seagen; Takeda; Trieza Therapeutics
Research Funding - Abbvie; Adaptimmune; Amgen; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Fate Therapeutics; Genentech; Genmab; Ignyta; Infinity Pharmaceuticals; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; Loxo; MedImmune; Merck; Mirati Therapeutics; miRNA Therapeutics; Molecular Templates; MOLOGEN; National Cancer Institute; Novartis; Pfizer; Seagen; Takeda
Travel, Accommodations, Expenses - Genmab; Loxo; miRNA Therapeutics